Monday, September 25, 2017 10:15 PM ET
Significant Insider Buying Reverses Sale Trend of Last 90 Days in Shares of Acceleron Pharma (XLRN)
There was noteworthy buying activity in Acceleron Pharma shares by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Celgene Corp, 10% Owner — purchased 745,592 shares in the company having a market value of approximately $27,586,904. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the selling of 58,626 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 686,966 shares and have averaged 134,036 shares per transaction over this time period.
In relation to the peer group over the last 90 days, insider buy/sell trading at Acceleron Pharma is higher than the 266-company peer group average. Bio Therapeutic Drugs peer group saw 305 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for Acceleron Pharma insiders was also higher. Within the peer group there were 8,560,303 shares purchased and 15,581,997 shares sold with company insiders disposing of 23,022 shares on average.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data obtained to create and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.